Project Grant K99DK138293
Award Date
8/1/24
Completion Date
5/31/26
Dollars Obligated
$273K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The National Cancer Institute (NCI) awarded a 5-year, $646,739 Project Grant (CFDA 93.396 - Cancer Biology Research) to Cedars-Sinai Medical Center to investigate the role of hepatic stellate cells (HSCs) in promoting liver metastasis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The research aims to elucidate the regulatory mechanisms and functional roles of extra-tumoral and intra-tumoral HSCs, as well as the impact of extracellular matrix (ECM)...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $740,040 to Xylyx Bio, Inc. to develop and validate a liver fibrosis cell-based assay platform. The platform will use engineered human liver fibrotic lesions integrated with patient-derived stellate cells, Kupffer cells, and hepatocytes to enable predictive in vitro testing of anti-fibrotic...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $172,060 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the role of the unfolded protein response (UPR) in the pathogenesis of non-alcoholic steatohepatitis (NASH). The research aims to understand the mechanism of UPR loss...
This three-year, $3.13 million project grant from the National Institutes of Health's National Institute of Environmental Health Sciences will fund research at Michigan State University investigating the progression of non-alcoholic fatty liver disease. Specifically, the grant will test the hypothesis that activation of the aryl hydrocarbon receptor by environmental contaminants reprograms fatty acid metabolism, causing the accumulation of toxic lipid intermediates that contribute to...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $1,123,570.00 to Virginia Commonwealth University from September 1, 2024 to July 31, 2028 to conduct research on the role of circular RNAs in cholestatic liver diseases, particularly primary sclerosing cholangitis (PSC). The research aims to examine how H19-induced upregulation of specific circular RNAs,...
This Project Grant award of $306,324 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will fund research by the Oklahoma Medical Research Foundation (OMRF) to map the life cycle of myofibroblasts in skin wound healing. The project aims to create a molecular profile of how fibroblasts differentiate into myofibroblasts and then revert to a deactivated state, with a focus on...
This Project Grant award of $1,508,800.00, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research conducted by The University of Texas Southwestern Medical Center (UT Southwestern) to elucidate the role of somatic genetics in chronic liver disease pathways. The research aims to 1) identify adaptive genetic pathways specific to liver disease etiologies,...
This $127,952 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support research at George Washington University to study the role of the enzyme HDAC11 in liver cancer progression. The research has two main aims: 1) to determine if HDAC11-mediated modifications to the splicing factor SF3B2 impact alternative mRNA splicing in liver cancer cells, and 2) to evaluate the potential of HDAC11-specific inhibitors as a new liver cancer treatment...
This federal Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research at the Pennington Biomedical Research Center to examine the role of the mitochondrial protein SLC25A25 in the onset and progression of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)....
This $705,405 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to investigate the role of adventitial fibroblasts, an understudied cell population, in the development and progression of atherosclerosis. The key objectives are to: Determine the mechanism by which targeted genetic ablation of adventitial fibroblasts decreases atherosclerotic plaque formation, despite these cells not directly contributing to the intimal...